Network Version
Monomethyl auristatin E Data Sheet
| Product Name: | Monomethyl auristatin E |
 |
|---|---|---|
| CAS No.: | 474645-27-7 | |
| Cat. No.: | HY-15162 | |
| MWt: | 717.98 | |
| Formula: | C39H67N5O7 | |
| Purity : | >98% | |
| Solubility: | Ethanol : 50 mg/mL (69.64 mM; Need ultrasonic); DMSO : ≥ 48 mg/mL (66.85 mM) | |
| Mechanisms: | Target: Cancer | |
| Biological Activity: | ||
| Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types. IC50 & Target: Microtubule[1] In Vitro: Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells[1]. MMAE sensitizes colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells[2]. In Vivo: Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolongs tumor regression in xenograft models[2]. | ||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com